DUBLIN–(BUSINESS WIRE)–The “Dyskinesia – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.
The review provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 16, 9, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
- Addex Therapeutics Ltd.
- Amarantus Bioscience Holdings Inc.
- Astraea Therapeutics LLC
- Cadent Therapeutics Inc.
- Cannabis Science Inc.
- Cavion LLC
- Cerevance Inc.
- Clevexel Pharma SAS
- Contera Pharma ApS
- DanPET AB
- EpiVax Inc.
- GW Pharmaceuticals PLC
- H. Lundbeck AS
- Hua Medicine Shanghai Ltd.
- Ipsen S.A.
- IRLAB Therapeutics AB
- Junaxo Inc.
- Med-Life Discoveries L.P.
- Medytox Inc.
- Melior Pharmaceuticals II LLC
- Merz Pharma GmbH & Co. KgaA
- MitoDys Therapeutics Ltd.
- Motac Neuroscience Ltd.
- NeurAxon Pharma Inc.
- Neurim Pharmaceuticals Ltd.
- Neurocea Pharmaceuticals
- Neurocrine Biosciences Inc.
- Neurolixis Inc.
- Newron Pharmaceuticals S.p.A.
- Nissan Chemical Corp.
- OB Pharmaceuticals
- Peptron Inc.
- PolyCore Therapeutics LLC
- Praxis Precision Medicines Australia Pty. Ltd.
- Prilenia Therapeutics Development Ltd.
- Revance Therapeutics Inc.
- Sage Therapeutics Inc.
- SalubRx Therapeutics Inc.
- Sinopia Biosciences Inc.
- SOM Biotech SL
- Sosei Heptares
- Trevi Therapeutics Inc.
- Ultragenyx Pharmaceutical Inc.
- VistaGen Therapeutics Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/og4htj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900